Cascade Pharmaceuticals Secures RMB140 Million in Financing to Advance FXR Agonist Clinical Trials
Shanghai-based sino-foreign joint venture, Cascade Pharmaceuticals, Inc., has reportedly raised RMB140 million in a recent...
Insight, China's Pharmaceutical Industry
Fineline Insights, Pharma Clarity